Journal of Crohn's and Colitis
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Effectiveness and Safety of Advanced Combination Treatment (ACT) in patients with refractory inflammatory bowel disease or concomitant immune mediated disease or extra-intestinal manifestations: A Multi-Center Canadian Study
2025
-
Adaptive Steroid Tapering Impedes Corticosteroid-free Remissions Compared with Forced Tapering in Clinical Trials of Ulcerative Colitis
2024
-
MB310: From Clinical FMT to a Phase 1 Study with a Defined, Orally Administered Live Bacterial Therapeutic for Mild Moderate Ulcerative Colitis
2024
-
OP05 Association of ultra-processed food intake with risk of Inflammatory Bowel Disease from the prospective urban rural epidemiology (PURE) study: A prospective cohort study
2021
-
A randomised, placebo-controlled pilot trial of faecal microbiota transplantation for paediatric Crohn's disease
2020
-
Effectiveness and safety of ustekinumab in patients with Crohn's disease: a real-world experience
2020
-
Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study
2020
-
Feasibility of the first paediatric randomised controlled pilot trial of faecal microbiota transplant for ulcerative colitis
2020
-
Ileal ulcer size significantly impacts the ability to achieve endoscopic remission: a post-hoc analysis from the SONIC trial
2020
-
Perceptions of faecal microbiota transplantation in patients with ulcerative colitis
2020
-
Qualitative perspectives of parent and child participants from a trial of faecal microbiota transplant for paediatric ulcerative colitis
2020
-
Results of the first paediatric randomised controlled trial of faecal microbiota transplant for ulcerative colitis
2020
-
Mode of delivery and risk of inflammatory bowel disease
2019
-
Surveillance colonoscopies in ulcerative colitis: does it make a difference?
2019
-
P071 Supporting extrapolation of indications for ABP 501, the first adalimumab biosimilar: focus on Crohn’s disease
2019
-
P607 Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease
2019
-
P847 Perceptions of faecal microbiota transplantation in a paediatric ulcerative colitis population (PediFETCh Trial)
2019
-
Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open
2018
-
Higher adalimumab maintenance regimens are more effective than standard maintenance doses in Crohn's disease patients who have failed infliximab
2018
-
Incidence of venous thromboembolic complications in controlled trials of inflammatory bowel disease
2018
-
Pre-operative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease: A systematic review and meta-analysis
2018
-
Systematic review and meta-analysis: Patient-reported outcomes and endoscopic appearance in ulcerative colitis
2018
-
P191 Systematic review and meta-analysis: Patient-reported outcomes and endoscopic appearance in ulcerative colitis
2018
-
C-reactive protein improvement after vedolizumab induction phase is associated with remission after 6 months of treatment in ulcerative colitis patients
2017
-
Early use of therapeutic drug monitoring to individualize infliximab therapy in paediatric IBD: a multicentre prospective COHORT study
2017
-
Impact of adalimumab's patient support program on clinical outcomes in inflammatory bowel diseases: results from the COMPANION study
2017
-
Increasing treatment time on REMICADE (R) (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada
2017
-
Persistent symptoms, CRP elevation and treatment changes over time in Crohn's disease patients are associated with bowel damage progression as expressed by deterioration of Lemann Index score
2017
-
Proximal disease extension in limited ulcerative colitis: a systematic review and meta-analysis
2017
-
Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011
2017
-
Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment
2017
-
Anxiety and depression may lead to poor health-related quality of life in patients with inflammatory bowel disease
2016
-
Canadian patient and caregiver perspectives on subsequent entry biologics/biosimilars for inflammatory bowel disease
2016
-
Impact of high-dose vitamin D3 supplementation in treatment of Crohn's disease in remission: a randomised double-blind controlled study
2016
-
Living with inflammatory bowel disease: results from focus group
2016
-
Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study
2016
-
Clinical value of routine therapeutic anti-TNF drug monitoring (TDM) in Inflammatory Bowel Disease (IBD) patients in clinical practice
2015
-
Correlation between the Ulcerative Colitis Endoscopic Index of severity (UCEIS) and intestinal mucosal calprotectin (IMC) in acute severe ulcerative colitis.
2015
-
Systematic Review and Meta-Analysis: Infliximab or Ciclosporin as Rescue Therapy in Patients with Severe Ulcerative Colitis Refractory to Steroids
2015
-
DOP040 Anti-TNF-α therapies are safe during pregnancy in patients with inflammatory bowel disease: a meta-analysis
2014
-
P309 Transition experience from inpatient to ambulatory IBD care: Results of a pilot study
2014
-
Spatial mapping and geographic variation of inflammatory bowel disease in Canada: A population-based study..
jjaf079.
2025
-
5-Aminosalicylates for non-Surgical Patients With Active or Quiescent Crohn's Disease: An Overview Of Systematic Reviews (Umbrella Review)..
jjaf069.
2025
-
Definitions, diagnosis, and management of postoperative recurrence in Crohn's disease patients with permanent ileostomy-a systematic review and meta-analysis..
19:jjaf041.
2025
-
Novel outcomes in inflammatory bowel disease..
19:jjaf040.
2025
-
Use of Modified Multiplier of the Simple Endoscopic Score for Crohn's Disease Endoscopic Improvement Thresholds Enhances Effect Size Differentiation Between Adalimumab Versus Placebo: A Post Hoc Analysis of the EXTEND Trial..
19:jjae171.
2025
-
Outcomes of Patients With Prior Biologic Intolerance Are Better Than Those With Biologic Failure in Clinical Trials of Inflammatory Bowel Disease..
19:jjae151.
2025
-
A systematic review and quality assessment of clinical practice nursing guidelines for ostomy care.
19:I1754-I1755.
2025
-
Increasing rate of hospitalization for inflammatory bowel disease is an age-related effect: A Canadian population-based study.
19:i2177-i2178.
2025
-
Interventions for ocular extraintestinal manifestations in inflammatory bowel disease: an umbrella review of systematic reviews.
19:i1415-i1416.
2025
-
Interventions for rheumatological extraintestinal manifestations in Inflammatory Bowel Disease: an umbrella review of systematic reviews.
19:i1836-i1837.
2025
-
Patients with refractory and difficult-to-treat Inflammatory Bowel Disease are underrepresented in randomized clinical trials.
19:I2114-I2115.
2025
-
Placebo rates in randomised clinical trials of Ulcerative Colitis: An individual patient data meta-analysis.
19:i1100-i1101.
2025
-
Spatial mapping and geographic variation of inflammatory bowel disease in Canada: A population-based study using Statistics Canada data.
19:I2177-I2178.
2025
-
The effectiveness of medical therapies for dermatological extraintestinal manifestations in patients with IBD: an umbrella review.
19:i2075-i2076.
2025
-
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease..
19:jjaf006.
2025
-
Pharmacological Therapies for the Management of Fistulizing Crohn’s Disease: A Systematic Review and Meta-Analysis.
18:589-603.
2024
-
Outcomes Following Acute Severe Colitis at Initial Presentation: A Multi-centre, Prospective, Paediatric Cohort Study.
18:233-245.
2024
-
Efficacy and Safety of Advanced Oral Small Molecules for Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
17:1800-1816.
2023
-
Combined Histological and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared with Endoscopic Improvement Alone in Ulcerative Colitis: A Post hoc Analysis of the VARSITY study.
17:1114-1121.
2023
-
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions.
17:1066-1078.
2023
-
Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis.
17:644-658.
2023
-
Beyond the White Pill: Advocating for Racial Diversity in IBD Trials.
17:459-461.
2023
-
Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies.
17:404-417.
2023
-
Time to Endorse A Sensitive Method for Scoring Endoscopic Activity of Ulcerative Colitis in Clinical Research.
17:302-304.
2023
-
Placebo Rates in Randomized Controlled Trials of Proctitis Therapy: A Systematic Review and Meta-Analysis Placebo Response in Proctitis.
17:123-136.
2023
-
Categorising Endoscopic Severity of Crohn’s Disease Using the Modified Multiplier SES-CD [MM-SES-CD].
16:1011-1019.
2022
-
Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease.
16:768-777.
2022
-
Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn’s Disease.
16:616-624.
2022
-
The Phenotypic Spectrum of New-onset IBD in Canadian Children of South Asian Ethnicity: A Prospective Multi-Centre Comparative Study.
16:216-223.
2022
-
Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn’s Disease: A Post-hoc Analysis.
15:1649-1657.
2021
-
Prevalence and Progression of Incidental Terminal Ileitis on Non-diagnostic Colonoscopy: A Systematic Review and Meta-analysis.
15:1455-1463.
2021
-
End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn’s Disease.
15:1114-1119.
2021
-
Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn’s Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials.
15:462-470.
2021
-
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment.
14:155-168.
2020
-
P375 Feasibility of the first paediatric randomised controlled pilot trial of faecal microbiota transplant for ulcerative colitis.
14:S353-S354.
2020
-
P416 Results of the first paediatric randomised controlled trial of faecal microbiota transplant for ulcerative colitis.
14:S379-S380.
2020
-
P517 A randomised, placebo-controlled pilot trial of faecal microbiota transplantation for paediatric Crohn’s disease.
14:S447-S448.
2020
-
P534 Qualitative perspectives of parent and child participants from a trial of faecal microbiota transplant for paediatric ulcerative colitis.
14:S456-S457.
2020
-
P841 Evaluation of gut microbiota composition in NAFLD with UC pancolitis in clinical remission: a pilot study.
14:S650-S651.
2020
-
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
14:4-22.
2020
-
Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease.
12:538-545.
2018
-
P735 Incidence of venous thromboembolic complications in controlled trials of inflammatory bowel disease.
12:s483-s484.
2018
-
Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis.
11:jjw174-jjw174.
2017
-
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
10:925-933.
2016
-
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies.
9:945-965.
2015
-
Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis.
8:571-581.
2014
-
Bell's palsy in a patient receiving adalimumab for Crohn's disease.
7:e115-e115.
2013
-
Resource utilization during pediatric to adult transfer of care in IBD.
7:e55-e60.
2013
-
Management of inflammatory bowel disease with vitamin D: Beyond bone health.
6:397-404.
2012
-
Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
6:77-85.
2012
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)